Business
Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the ...
About this update from Arch Biopartners, Inc.
[{"type":"text","content":"Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide\nTORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s Hospital (SMH), part of Unity Health Toronto, has commenced patient dosing in Arch’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). St. Michael’s Hospital is the third Canadian site to successfully recruit patients in the CS-AKI Phase II trial. Along with SMH, Toronto General Hospital, part of University Health Network (Ontario) and the University of Calgary Cumming School of Medicine (Alberta) continue to actively recruit new patients in the trial. At Royal Columbian Hospital (British Columbia), site start-up activities are ongoing in advance of commencing patient recruitment. Update on the CS-AKI Phase II Trial The Company’s blinded review of trial data indicates that AKI has been consistently observed using the protocol-defined criteria, supporting the trial’s study design and defined endpoints. At this time, investigators and medical monitors have not assessed any adverse events or serious adverse events as related to LSALT peptide. There have been no SUSARs (suspected unexpected serious adverse reactions) reported in the trial. The Company is currently progressing feasibility and start-up discussions with additional leading cardiac surgery centres in Canada and the United States. Expanding to selected U.S. sites is intended to broaden clinical awareness of LSALT peptide among cardiac surgery and kidney care specialists, while also supporting the acceleration of patient recruitment. Discussions with prospective clinical sites have included site evaluations, investigator commitments to perform the trial, budget development, and drafting clinical trial agreements. Three prospective sites in the U.S. and one additional site in Ontario (to participate through Clinical Trials Ontario) are currently under consideration. The addition of new clinical sites to the CS-AKI Phase II trial will be subject to the execution of clinical trial agreements. In Turkey, the Company has submitted required...